ROIV

Roivant Sciences Ltd.
CAPPED RATING

Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch \"Vants\" - nimble and focused biopharmaceutical and health technology companies

Roivant Sciences Ltd. (ROIV) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Value (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
F
Factor Score 0.1 / 5.0
Growth
B-
Factor Score 2.9 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
B
Factor Score 3.5 / 5.0
Revisions
F
Factor Score 0.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -24.5
EV / EBITDA N/A
Rev Growth YoY N/M
Gross Margin 0.0%
Price Return 3M 9.1%
Price Return 12M 85.4%
Catalyst Signal +0.09
Market Cap $28.6B
TTM Revenue $41.1M
Price / Sales 697.2
ROE -8.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 F (0.1) B- (2.9) C (2.3) B (3.5) F (0.6) C- (1.9)
2026-11-09 F (0.0) D+ (1.6) D+ (1.6) B+ (3.5) F (0.6) D (1.5)
2026-11-02 F (0.0) D+ (1.5) D+ (1.7) B+ (3.7) F (0.6) D (1.5)
2026-10-30 F (0.0) D (1.2) D+ (1.7) B (3.4) D+ (1.6) D+ (1.6)
2026-10-26 F (0.0) D (1.2) D+ (1.7) B (3.3) C (2.4) D+ (1.7)
Page 1 of 4